BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Galapagos Genomics NV Signs Research Collaboration Agreement With Novartis Pharmaceuticals UK Limited (NVS)


10/19/2005 5:09:25 PM

MECHELEN, Belgium, July 6, 2005 (PRIMEZONE) -- Galapagos announced today that it has entered into a research collaboration with Novartis Pharmaceuticals UK Limited. Under the agreement, Galapagos' genomics partnering division Galadeno will design a research program for Novartis employing its SilenceSelect(R) (gene knock-down) platform for functional assays in human primary cell assays. The SilenceSelect technology is based on Galadeno's collection of adenoviruses with human gene sequences that specifically knock down over 4,000 different human proteins by producing siRNA in a human cell.Under the terms of the agreement, Galadeno will provide technology, reagents and support to enable Novartis to validate drug targets by analyzing human protein function in human primary cells. Galadeno will receive payments related to the research services and its SilenceSelect technology. "We are very pleased that Novartis Pharmaceuticals has decided to work with Galapagos for its expertise in knock-down technology and cellular assays. This collaboration will allow Novartis Pharmaceuticals UK Limited to utilize our SilenceSelect target discovery engine in a very beneficial way", says Onno van de Stolpe, CEO of Galapagos. "We are confident that our technology will perform well in the hands of Novartis. Our SilenceSelect platform has proven to deliver for our other partners, opening significant opportunities for continued collaboration."

Read at Prime Zone

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES